Stock Events

Stock Events

Gain Therapeutics 

$2.01
45
+$0.02+1.26% Friday 19:59
-$0.00-0.25%Friday 23:30After hours

Statistics

Day High
2.01
Day Low
2
52W High
4.34
52W Low
1.53
Volume
5,210
Avg. Volume
-
Mkt Cap
87.51M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.19
-0.15
-0.12
-0.08
Expected EPS
-0.124
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-20.16MNet Income

Analyst Ratings

6.50Average Price Target
The highest estimate is 8.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GANX. It's not an investment recommendation.
NVIDIA
5
NVDA
Alphabet
5
GOOGL
Vanguard S&P 500
5
VOO
Rocket Lab
5
RKLB

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.91B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for genetic diseases, similar to Gain Therapeutics' focus on genetic disorders.
Biogen
BIIB
Mkt Cap32.03B
Biogen competes in the neurodegenerative diseases space, overlapping with Gain Therapeutics' work on Parkinson's and other CNS disorders.
PTC Therapeutics
PTCT
Mkt Cap5.98B
PTC Therapeutics operates in the rare diseases sector, making it a direct competitor to Gain Therapeutics, which also targets rare genetic disorders.
CRISPR Therapeutics
CRSP
Mkt Cap5.75B
CRISPR Therapeutics is focused on gene editing, a competitive area for companies like Gain Therapeutics that are involved in genetic disorder treatments.
Novartis
NVS
Mkt Cap301.95B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for genetic disorders, competing with Gain Therapeutics' niche focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for genetic diseases, competing in the same space as Gain Therapeutics.
Sarepta Therapeutics
SRPT
Mkt Cap1.91B
Sarepta Therapeutics is known for its work on Duchenne muscular dystrophy and other genetic disorders, competing with Gain Therapeutics.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals develops RNA-targeted therapies, including for genetic disorders, placing it in direct competition with Gain Therapeutics.

About

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Show more...
CEO
Gene Mack
Employees
21
Country
United States
ISIN
US36269B1052

Listings

XNAS
US
GANX
BOATS
BOATS
GANX.BOATS

0 Comments

Share your thoughts

FAQ

What is Gain Therapeutics stock price today?▼
The current price of GANX is $2.01 USD — it has increased by +1.26% in the past 24 hours. Watch Gain Therapeutics stock price performance more closely on the chart.
What is Gain Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Gain Therapeutics stocks are traded under the ticker GANX.
Is Gain Therapeutics stock price growing?▼
GANX stock has fallen by -1.72% compared to the previous week, the month change is a +14.57% rise, over the last year Gain Therapeutics has showed a +1.78% increase.
What is Gain Therapeutics market cap?▼
Today Gain Therapeutics has the market capitalization of 87.51M
When is the next Gain Therapeutics earnings date?▼
Gain Therapeutics is going to release the next earnings report on November 18, 2026.
What were Gain Therapeutics earnings last quarter?▼
GANX earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.14 USD resulting in a +20.29% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Gain Therapeutics revenue for the last year?▼
Gain Therapeutics revenue for the last year amounts to 0 USD.
What is Gain Therapeutics net income for the last year?▼
GANX net income for the last year is -20.16M USD.
How many employees does Gain Therapeutics have?▼
As of August 24, 2026, the company has 21 employees.
In which sector is Gain Therapeutics located?▼
Gain Therapeutics operates in the Health & Wellness sector.
When did Gain Therapeutics complete a stock split?▼
Gain Therapeutics has not had any recent stock splits.
Where is Gain Therapeutics headquartered?▼
Gain Therapeutics is headquartered in BETHESDA, United States.